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Abstract

Cancer immunotherapy has become an effective treatment in the toolbox of
oncologists. Immunotherapy offers a less toxic alternative to standard cancer treatments
such as chemotherapy and can have prolonged curative effects to decrease cancer
recurrence. Today, many drugs and biological agents have been developed that target the
immune system and elicit an antitumor/cancer response. These agents are known
collectively as cancer immunotherapies. While immunotherapies have radically improved
treatment outcomes for many cancer patients, there are drawbacks to using these
treatments. Immunotherapy treatments have poor clinical responses in patients with tumors
that lack immunogenicity. Some of the treatments also pose a risk to induce systemic
toxicity when used at high doses and risks of autoimmunity are essentially inherent. To
mitigate these shortcomings of immunotherapies, biomaterials can be used as a delivery
vehicle to alter the pharmacokinetics, biodistribution, and control release of therapeutic
agents targeting the immune system. This review article outlines the general design
considerations of various biomaterials and their applications in cancer immunomodulation.
Many studies show promising results in murine tumor models with potential for translation
to human disease, but further research – via rigorous clinical trials – is needed to assess the
effectiveness of immunomodulatory biomaterials in cancer patients.

V

Table of Contents
List of Figures…………………………………………………………………………VIII
List of Abbreviations……………………………………………………………………IX
Introduction…………………………………………………………………………….....1
Local Immunomodulatory Biomaterials……………………………………………….....6
Hydrogels…………………………………………………………………............7
Design Considerations for Effective Drug Delivery…………………..….8
Synthetic and Natural Polymers…………………………………...…….11
Stimuli-Responsive “Smart” Hydrogels……………………………...... ..13
Scaffolds………………………………………………………………………....15
Injectable vs Surgical…………………………………………………....16
Design Parameters …………...………………………………………….19
Microparticles……………………………………………………………………22
Types of Microparticles and Their Applications………………………...24
Design Considerations…………………………………………………...30
Systemic Immunomodulatory Biomaterials……………………………………………..32
Nanoparticles…………………………………………………………………….33
Design Considerations…………………………………………………...37

VI

Types of Nanoparticles and Their Applications…………………………40
Drug Conjugates…………………………………………………………………47
Polymer-Drug Conjugates: Design Considerations………………….......48
Antibody-Drug Conjugates: Design Considerations…………………….51
Conclusion……………………………………………………………………………….53
References……………………………………………………………………………….55

VII

List of Figures

Table 1

US Food and Drug Administration Approved Cancer Immunotherapies

2

Figure 1

Representative Figure of Local and Systemic Drug Delivery

5

Figure 2

Relationship Between the Cross-Linking Density and Physical Properties
of the Hydrogel

10

Figure 3

Prophylactic Capability of Nanoplex DNA Vaccine Against Murine
B16/OVA Lung Melanoma

13

Figure 4

Process Schematic of Infection-Mimicking Scaffold Design by Ali

16

Figure 5

Prophylactic Cancer Vaccine Study Using Injectable, Spontaneously
Forming MSR Scaffolds

19

Figure 6

Various Release Mechanisms of Microparticle Systems

24

Figure 7

Murine B16F10 Melanoma Prophylactic Study Using Fe 3O44/T-MPsCpG/Lipo Vaccine

26

Figure 8

Therapeutic Efficacy of AntiCD40 and AntiCTLA-4 Microparticle
Formulation Against MC-38 Tumor Cells

29

Figure 9

Schematic of Cell Targeted Delivery of Immunotherapeutic Agents Using
Nanoparticles

36

Figure 10

Therapeutic Efficacy of Immunoliposome IL-2-Fc/αCD137 Therapy

42

Figure 11

Therapeutic Effect of Targeted Delivery of SD-208 Using Anti-PD-1
Tagged Nanoparticles

44

Figure 12

Therapeutic Effect of Targeted Delivery of R848 and Sensitization of
Tumors to PD-1 Blockade

45

Figure 13

In vivo Anti-Tumor Efficacy of P(L-SS-PTX), a Polymer-Paclitaxel Drug
Conjugate

50

Figure 14

Key Design Components of Antibody-Drug Conjugates

52

VIII

LIST OF ABBREVIATIONS

FDA

US Food and Drug Administration

IFN

interferon

IL

interleukin

PD

Programmed cell death protein

TLR

Toll-like receptor

GM-CSF

Granulocyte-macrophage colony-stimulating factor

APC

Antigen presenting cell

DC

Dendritic cells

MPS

Mononuclear phagocyte system

TME

Tumor microenvironment

ECM

Extracellular matrix

HA-PCLA

Poly (ε-caprolactone-co-lactide) ester-functionalized hyaluronic acid

HA

Hyaluronic acid

PELG

Poly (γ-ethyl-L-glutamate)

PLGA

Poly(lactic-co-glycolic acid)

PEG

Poly (ethylene glycol)

PLG

Poly-lactide-co-glycolide

mPEG-b-P(LLDTPA)

3,3’-dithiodipropionic acid functionalized methoxy poly(ethylene
glycol)-b-poly(L-lysine)

CpG-ODN

Unmethylated cytosine-phosphate-guanine oligonucleotide

STING

Stimulator of Interferon Genes

MSR

Mesoporous silica rods

OVA

Ovalbumin

GSH

Glutathione

TH1/2

Helper T cell subtype 1/2

IX

RGD/RDG

Integrin-binding ligand of Arg-Gly-Asp

T-MPs

Tumor microparticles

FITC-BSA

Bovine-fluorescein isothiocyanate

CTLA

Cytotoxic T lymphocyte antigen

pLHMGA

Poly (lactic-co-hydroxymethyl-glycolic acid)

IFA

Incomplete Freund’s adjuvant

MHC

Major histocompatibility complex

EPR

Enhanced permeability and retention effect

DOTAP

Dioleoylphosphatydic acid

PTX

Paclitaxel

X

Introduction
Immunotherapy has become a promising tool in the arsenal of cancer treatment
that utilizes the patient’s immune system to elicit robust, long-lasting anticancer responses.
Since the FDA approval of the use of IFN-α, a cytokine, in 1986 to treat leukemia, cancer
immunotherapy has made significant progress in the development of effective
immunomodulatory treatments with promising results in the fight against cancer [1-3]. These
treatments include checkpoint inhibitors, CAR T-cell therapy, cytokines, cancer vaccines,
monoclonal antibodies, and other immunomodulators that boost the cancer immune
response. Several immunomodulatory drugs and agents have been approved by the FDA
since 1986 (Table 1). Even though these treatments have proven effective, there are
shortcoming as well

[4]

. In particular, immunotherapy treatments using cytokines, cancer

vaccines, and immune checkpoint inhibitors have proven to be less effective in some
patients. One of the main issues in these non-responsive patients is a lack of
immunogenicity in tumors. Many immunotherapies elicit a change in key immune cells
such as dendritic cells (DC) or T-cells; however, tumors with poor immunogenicity, or
“cold” tumors, lack many of these cells or possess immune cells that oppose activation of
the immune system. Another issue that arises is the risk of systemic toxicity. Therapies
such as Interleukin-2 (IL-2) or programmed cell death protein 1 (PD-1) inhibitors can have
adverse off target effects and become toxic at high doses

[5-6]

. Due to this toxicity, only

small doses of the drugs can be used, so treatment must be focused to ensure the maximum
effectiveness of the drug. Additionally, using immunomodulatory agents can lead to the
1

development of an autoimmune response. In the case of cancer vaccines, treatments can be
ineffective due to a low number of transfections in DCs thus producing a weak anticancer
immune response.
Therapy

Type

Approved cancers

Year of
first
approval

CTLA4 mAb

Melanomaa

2011

PD-1 mAb

Melanomaa, non-small-cell
lung cancer, Hodgkin
lymphoma, advanced gastric
cancer, microsatellite
instability-high cancer, head
and neck cancer and
advanced urothelial bladder
cancer

2014

Nivolumab

PD-1 mAb

Melanomaa, bladder cancer,
classical Hodgkin lymphoma,
colorectal cancer,
hepatocellular cancer, non2014
small-cell lung cancer, kidney
cancer, squamous cell
carcinoma of the head and
neck and urothelial cancer

Atezolizumab

PD-L1 mAb

Urothelial cancera and nonsmall-cell lung cancer

2016

Avelumab

PD-L1 mAb

Merkel cell carcinomaa and
urothelial cancer

2017

Durvalumab

PD-L1 mAb

Urothelial cancera and nonsmall-cell lung cancer

2017

Checkpoint inhibitors
Ipilimumab

Pembrolizumab

Cytokines for lymphocyte promotion

Intron A

Hairy cell leukaemiaa,
melanoma, follicular
1986
lymphoma, and AIDS-related
Kaposi sarcoma

Recombinant IFNα2b
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Therapy

Type

Approved cancers

Year of
first
approval

Roferon-A

Recombinant IFNα2a

Hairy cell leukaemiaa,
chronic myelogenous
leukaemia and AIDS-related
Kaposi sarcoma

1986

Aldesleukin

Recombinant IL-2

Melanomaa and kidney
cancer

1992

Imiquimod

Stimulates TNF, IL-12
and IFNγ productionb

Basal cell carcinoma

2004

CD19-specific CAR T
Tisagenlecleucel
cells

B cell acute lymphocytic
leukaemiaa and non-Hodgkin
lymphoma

2017

Axicabtagene
ciloleucel

CD19-specific CAR T
cells

Large B cell lymphomaa

2017

Sipuleucel-T

Autologous PBMCs
activated with
recombinant human
PAP–GM-CSF

Prostate cancera

2010

Bacillus
Calmette–
Guérin

Strain of Mycobacterium
Bladder cancer
tuberculosis variant bovis

1990

Genetically modified
HSV type 1 designed to
replicate within tumours
and produce GM-CSF

Melanomaa

2015

B cell acute lymphocytic
leukaemiaa

2014

Engineered T cell therapies

Vaccines

Oncolytic viruses
Talimogene
laherparepvec

Bispecific antibodies
Blinatumomab

CD19 and CD3
bispecific antibody
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Table 1: US Food and Drug Administration (FDA)-approved caner immunotherapies. CAR, chimeric
antigen receptor; CTLA4, cytotoxic T lymphocyte antigen 4; GM-CSF, granulocyte–macrophage colonystimulating factor; HSV, herpes simplex virus; IFN, interferon; IL, interleukin; mAb, monoclonal antibody;
PAP, prostatic acid phosphatase; PBMC, peripheral blood mononuclear cell; PD-1, programmed cell death
1; PD-L1, PD-1 ligand 1. aFirst indication to be approved. bIncreases production of cytokines when topically
applied. Figure adapted from Ref [8].

Drug delivery can be broadly categorized into local delivery and systemic delivery
(Figure 1). In local drug delivery, the delivery system releases drugs or elicits a response
in the immediate proximity of the material. The most used biomaterials in local drug
delivery are hydrogels, scaffolds, and microparticles. Hydrogels and scaffolds provide a
three-dimensional environment for immune cell recruitment and dendritic cell/antigen
presenting cell (APC) programming using cancer antigens, as well as, spatiotemporal
control over the release of immunomodulatory drugs at local sites. Microparticles provides
an injectable platform for local immunotherapy with a targeted delivery system that focuses
drug release at the local site and controls the release of the drug. On the other hand, drugs
delivered systemically distribute throughout the body via the circulatory system. Systemic
drug delivery biomaterials rely on an accumulation of the biomaterial at the tumor site,
metastatic sites, and/or lymph nodes. These delivery devices typically include
nanoparticles and drug conjugates. Nanoparticles are widely used in systemic drug delivery
to deliver cancer vaccines and provide targeted immunomodulatory drug release to key
immune cells. Nanoparticles help protect the agents and provides a customizable platform
to suit numerous applications. Drug conjugation provides a simple approach to target
delivery of immunotherapy drugs as well as modify the drug’s pharmacokinetics by
4

prolonging circulation and reducing clearance by the mononuclear phagocyte system
(MPS).
To

overcome

the

shortcomings

of immunotherapy,

immunomodulatory

biomaterials can be developed as immunotherapy delivery systems to improve drug safety
and efficacy[7-9]. The application and design considerations of immunomodulatory
biomaterials will be discussed to show the validity of these materials to improve
immunotherapy treatment. Here, we review the various immunomodulatory biomaterials
that can be applied in cancer immunotherapy – for both local and systemic delivery
applications.

Figure 1: Representative figure of local and systemic drug delivery.

5

Local Immunomodulatory Biomaterials
When immunotherapy drugs are administered systemically, the patient can
experience systemic toxicity and other off-target side effects. Therefore, researchers started
to modify the immunotherapy drugs or package them in nanoparticles to increase their
safety for systemic administration; however, these treatments often lack sufficient
accumulation of the payload in tumors needed to elicit an antitumor immune response. To
overcome these issues, researchers are investigating a more local approach to
immunomodulation. To accomplish this, macroscale drug delivery devices and
biomaterials have been developed as promising therapeutic avenues. Taking a local
approach in immunomodulation of the tumor microenvironment (TME) allows for a
focused administration of the cancer treatment that directly affects the tumor and immune
cells that infiltrate the tumor. Current local immunomodulation biomaterials offer
numerous

advantages

over

systemic

immunomodulation

[10-13]

.

First,

local

immunomodulatory biomaterials only need low doses of immunomodulatory drugs/agents
which circumvents the issue of systemic toxicity and other side effects, such as vascular
leak syndrome and cytokine release syndrome. Local administration lowers the dose of
drugs necessary due to the proximity to the treatment site and often incorporate a targeting
mechanism. These targeting mechanisms can promote immune cell recruitment or target
circulating immune cells (e.g. antibodies conjugated to the payloads within the local
immunomodulatory biomaterials). In addition to the low dose requirement, local
biomaterials spatiotemporally control drug release to optimize the immune response. Local
6

immunomodulatory biomaterials can be customized with a variety of chemical,
mechanical, and physical properties that optimize the drug release profile. Of note,
important properties that control drug release from local biomaterials include the rate of
polymer degradation, diffusion mechanism, and affinity between the biomaterial and the
drug [12].
Many of the local biomaterials being developed can be classified as either
hydrogels, scaffolds, or microparticles. Hydrogels and scaffolds provide a 3-dimensional
(3D) environment that can be loaded with stimulatory factors to aid in the recruitment of
APCs, such as DCs. After the host’s immune cells infiltrate the mesh network of the
hydrogel or scaffold, immunomodulatory drugs such as cancer vaccines, anticancer
antigens, or adjuvants can be presented to the immune cells to prime an antitumor immune
response that hinders the growth or proliferation of cancer cells. Microparticles offer a
different approach to administer cancer vaccines or immunotherapy drugs that can
potentially target specific immune cells that are frequently found at the tumor site or target
cancerous cells themselves to deliver the payload. Local immunomodulatory biomaterials
have made significant strides in cancer treatment by changing the immunogenicity of the
tumor and by equipping the immune system with the materials for a targeted and sustained
antitumor response.

Hydrogels
Hydrogels are injectable biomaterials that can be made from various polymers,
including natural polymers, synthetic polymers, or a hybrid composite of the two, that cross

7

links to form a 3D network. In comparison to the other local immunomodulatory
biomaterials, hydrogels have high biocompatibility, biodegradability, and customizability.
Another quality of note is the hydrophilic properties of hydrogels and their large swelling
ratio that creates a conducive environment that aids in immune cell maturation and
proliferation. Hydrogels can be used to hold numerous types of immunomodulatory agents
depending on the properties of the polymers and the porosity of the hydrogel. Hydrogels
can also be made responsive to environmental stimuli. Depending on the stimulus, it can
cause the sol-gel transition of the hydrogel or could impact the drug release mechanism.
The unique characteristics of hydrogels make them promising materials for drug delivery,
sparking interest in various research areas, including tissue engineering [20] and cancer
immunotherapy [13,15-16].
Hydrogels: Design Considerations for Effective Drug Delivery
In designing effective hydrogels for local immunomodulation, one must consider
multiple parameters that will affect the drug release profile, biocompatibility, and the
number of biological agents that can be loaded into the matrix. These parameters can
include the polymer volume fraction in the hydrogel, the polymer type, the diffusion
coefficient of the matrix, shear rate, and many more factors that can greatly impact the
effectiveness of treatment

[13,15,17-18]

. Hydrogels can be used to immobilize numerous

immunomodulatory agents; however, the size of the agents that can be stored within the
polymer mesh of the hydrogel is controlled by the size of the meshwork and its porosity
[15]

. The porosity of hydrogels is determined by the distance between neighboring cross-

links between polymers. As the number of cross-links (or the cross-linking density)
increases within the hydrogel network, the size of the pores decreases, limiting the size of
8

biological agents that can be loaded into the hydrogel and impacting immune cell
infiltration. Cross-linking density also dictates the shear rate, diffusion coefficient, and
swelling volume of hydrogels. The shear rate of hydrogels affects the injectability of the
biomaterial. Generally, the viscosity of the hydrogel solution increases as the weight
percent of polymer is increased. The diffusional capabilities of hydrogel aids in the ability
to provide a space for immune cell proliferation as well as a matrix to control the release
of immunomodulatory agents. The swelling volume dictates the hydrogels ability to swell
from the interactions between the hydrophilic polymers of the matrix and the aqueous ECM
thus creating a conducive environment for immune cell infiltration and proliferation. A
visual representation of the impact cross linking density has on the physical properties of
the hydrogel can be found in Figure 2. Cross linking density is an important factor that
impacts the deliverability of the hydrogel and subsequent drug release and immune cell
infiltration.

9

Figure 2: Relationship between the cross-linking density and the physical properties of the hydrogel. Two
visual representations of hydrogel structures with a low cross-linking density (left image) and a high crosslinking density (right image) are included along with a graphical representation of how the properties of the
hydrogel change as cross-linking density increases. The properties include the shear modulus (G),
equilibrium volumetric swelling ratio (Q), diffusivity (D), and mesh size (ξ). Figure adapted from Ref [15].

The chemical properties of hydrogels critically impact clinical application and
effectiveness[18]. The charge and the hydrophilicity of the polymeric chains in the hydrogel
affect hydrogel swelling from aqueous solutions such as water and biological interstitial
fluid. Chemical properties of the hydrogel polymers influence compatibility between the
biomaterial and the immunomodulatory agents. Chemical interactions, either repulsive or
attractive, between the polymeric meshwork and the immunomodulatory agents impact the
diffusional capabilities of the biomaterial. By modifying the chemical and physical
properties of hydrogels, researchers can create a library of different hydrogels that are
optimized for local immunomodulatory drug delivery.
10

Hydrogels: Synthetic and Natural Polymers
Hydrogels can be created using a variety of polymers categorized as natural-based,
synthetic-based, or a combination of the two[13, 19-21,58]. Natural polymers have intrinsic
bioreactive and biocompatible properties that closely mimics the ECM. Natural polymers
have a high degree of biodegradability and degrade into natural byproducts that are easily
cleared by the body. Synthetic polymers typically are nonimmunogenic and often do not
interact with the cellular environment. To encourage biological interactions, synthetic
polymers can be conjugated to biological ligands and proteins recognizable by host cells.
Some synthetic polymers pose a risk of toxicity

[76]

because of issues of biocompatibility

or with its degradation products, but many synthetic polymers used in hydrogel
development are FDA-approved. These features of natural and synthetic polymers should
be taken into consideration when developing an immunomodulatory hydrogel.
The choice to use a natural polymer or a synthetic polymer is based on a variety of
physicochemical, mechanical, and biological parameters and guided by the intended use of
the biomaterial. For instance, hydrogels made from collagen or gelatin are used widely in
tissue engineering because of their prominent roles in the native extracellular matrix
(ECM)

[20]

. Collagen and gelatin have natural chemical properties that make it highly

bioreactive and easily transition to a gel; however, these polymers generally form
hydrogels that are structurally weaker than synthetic alternatives. To overcome limitations
of hydrogels composed of purely natural or synthetic polymers, hybrid polymers are being
studied to combine the best features of natural and synthetic polymers. In one study,
researchers developed a hybrid hydrogel composed of levodopa, a stabilizing agent to slow
biodegradation, and poly(ε-caprolactone-co-lactide) ester-functionalized hyaluronic acid
11

(HA-PCLA) [22]. Hyaluronic acid (HA) is a natural polysaccharide and component of ECM
in connective tissue that impacts biological processes such as cell migration and
proliferation. Alone, hyaluronic acid hydrogels have high batch-to-batch variability,
rapidly biodegrade (detrimental depending on the application), and are often contaminated
[21]

. By combining HA and PCLA, the researchers were able to create a hydrogel that is

capable of transitioning to a gel state when the solution reaches body temperature and retain
the desired properties of HA, mainly its high biocompatibility. These hydrogels were able
to deliver granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance
immune cell recruitment to the hydrogel and a nanopolyplex-based DNA vaccine. To test
the prophylactic capabilities of the hydrogel formulation, mice were first immunized with
the hydrogel containing GM-CSF and the vaccine followed by an injection of B16/OVA
melanoma cells a week later. As seen in Figure 3, mice immunized with the hydrogel
containing both the recruiting cytokine and the vaccine had a significantly lower tumor
index compared to free administration of the cytokine and vaccine (P < 0.001). Compared
to hydrogels composed of only PCLA, using hybrid hydrogels composed of HA and PCLA
significantly lowered the tumor index in the prophylactic study (P < 0.05). Using the hybrid
hydrogels loaded with GM-CSF and the nanopolyplex-based vaccine elicited a strong
antitumor response that provided continuous protection in some mice after 4 weeks from
the melanoma inoculation. Hydrogels composed of only natural or synthetic polymers
show promise as local immunomodulatory biomaterials; however, hybrid hydrogels offer
a promising avenue to create novel delivery systems combining positive properties of each
material class.
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Figure 3: Prophylactic capability of nanoplex DNA vaccine against murine B16/OVA lung melanoma.
C57BL/6 mice were inoculated with melanoma cells 1 week after receiving hydrogel-based cancer vaccine
followed by a booster vaccine on day 14. Mice lungs were collected after 4 weeks and foci were quantified
under dissecting microscope. Treatment groups from left to right are negative control, OVA-loaded HAPCLA, (OVA + GM-CSF)-loaded HA-PCLA, free polyplex, free polyplex + GM-CSF, polyplex-loaded
PCLA, (polyplex + GM-CSF)-loaded PCLA, polyplex-loaded HA-PCLA, (polyplex + GM-CSF)-loaded
HA-PCLA. The graph above indicates the tumor index calculated as the average of (lung weights x grade)
for each group. The error bars in the graph indicates mean ± SD (n = 4). Data were analyzed using Student’s
t-test (*P < 0.05, **P < 0.01, ***P < 0.001). Figure adapted from Ref [22].

Hydrogels: Stimuli-Responsive “Smart” Hydrogels
The customizability of hydrogels allows for hydrogels to be designed to respond to
various environmental stimuli, including pH, temperature, oxidative stress, and enzymatic
activity, among other cues

[58]

. For example, a temperature stimulus can be utilized to

trigger the sol-gel transition after injection of the hydrogel solution. Once the solution
reaches body temperature, the solution will become more viscous and swell until it reaches
13

a gel state. This phase change is due to a destabilizing effect on the hydrophobic
interactions between the polymers and hydrophilic interactions with the surrounding
extracellular fluid. The thermoresponsive property of hydrogels is affected by the
concentration of thermoresponsive polymers. In one study, researchers developed a
thermoresponsive triblock copolymer hydrogel composed of poly(γ-ethyl-L-glutamate)
(PELG) and poly (ethylene glycol) (PEG) arranged as PELG-b-PEG-b-PELG

[23]

. The

required temperature to start the sol-to-gel phase transition decreased as the polymer
concentration increased from 3 wt% to 6 wt% of the hydrogel solution. Thus, changes as
simple as the polymer concentration in hydrogel solutions cause changes in the gelling
process and must be taken into consideration when designing an injectable system.
Carefully modifying the sol-gel transition allows for the hydrogel to be injected at the target
site and form the biomimicking matrix to recruit immune cells or deliver
immunomodulatory agents.
The pH of the microenvironment can cause certain hydrogels to switch chemical,
mechanical, and physical properties. These pH responsive hydrogels respond differently to
pH levels depending on the functional groups associated with the polymer [13,18]. Polymers
with acidic groups cause hydrogels to swell as pH increases due to the deprotonation of
acidic R groups. On the other hand, polymers with basic R groups cause hydrogels to swell
when the pH decreases. Stimuli-responsive hydrogels offer “smart” systems capable of
responding to their microenvironment and tightly regulating material response based on
biological processes occurring within the microenvironment.

14

Scaffolds
Scaffolds are 3D polymeric networks with applications in host cell recruitment and
spatiotemporal drug release. Scaffolds and hydrogels have similar functional properties
that allow for researchers to interchange between the two platforms. Scaffolds can be used
in a variety of ways to enhance local immunomodulation. Polymeric scaffolds loaded with
recruitment factors, such as GM-CSF, can promote immune cell recruitment into the
scaffold matrix where the immune cells can be exposed to cancer vaccines, antitumor
antigens, or adjuvants to aid in immune cell maturation. Afterward, those newly
programmed immune cells can leave the scaffold to aid in an antitumor immune response.
For example, in an intriguing study Ali et al. developed a macroporous poly-lactide-coglycolide (PLG) scaffold loaded with GM-CSF, danger signals (unmethylated cytosinephosphate-guanine oligonucleotide, or CpG-ODN), and tumor antigens to recruit and
reprogram DCs to elicit an antitumor response

[24]

(Figure 4). A dendritic cell-activating

scaffold, based on the technology developed by Ali et al., that contains melanoma cell
lysates is currently in phase I clinical testing. Scaffolds have also been used to act as a
delivery system for T-cells programmed in vitro such as CAR-T cell therapies

[25]

. These

scaffolds, loaded with CAR-T cells and STING agonists, improve T cell infiltration into
solid tumors and improve the elimination of malignant tumor cells. Scaffolds are generally
fabricated ex vivo and then must be implanted at the target site; however, there are some
formulations of scaffolds that are injectable, specifically mesoporous silica rods (MSRs)
[26,51]

.
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Figure 4: Process schematic of Ali et. al. infection-mimicking scaffold design. Stage 1: Recruit naïve
dendritic cells and APCs using released GM-CSF. Stage 2: The recruited dendritic cells/APCs reside in the
matrix of the scaffold to be programmed using preloaded cancer antigens. Stage 3: The newly programed
dendritic cells/APCs leave the scaffold to activate T-cells and initiate an anticancer immune response.

Scaffolds: Injectable vs. Surgical
Surgery has always been a prominent part of the treatment course for oncology
patients that has curative results, but surgical procedures are not without risk. Implantable
scaffolds are often placed either at the tumor resection site to lower the chances of relapse
or placed subcutaneously near a lymph node to recruit and reprogram immune cells. Many
of the implantable scaffolds in development are composed of PLG due to its long-standing
16

FDA approval, record of biocompatibility, and material tunability. In one study of note on
implantable scaffolds, the 3D printed PLGA scaffold developed by Yang et al. acted as a
drug delivery device for combination chemotherapy using 5-fluorouracil and NVPBEZ235, known as PFN scaffolds

[48]

. Like immunotherapy drugs, chemotherapy drugs

lead to systemic toxicity at high doses. By incorporating chemotherapy locally via the
polymeric scaffold, researchers created a local drug delivery system to influence the TME
while diminishing systemic toxicity. In a therapeutic efficacy study conducted over 4
weeks, the average tumor volume of mice that received the PFN scaffold was 600 mm 3
compared to an average tumor volume of 1000 mm 3 in mice that received an intraperitoneal
injection of both chemotherapeutic drugs at equal concentrations every 3 days. This
combinational therapy delivered by the PLGA scaffold effectively slowed tumor growth in
a murine MDA-MB-231 orthotopic breast cancer model.
To avoid the limitations of surgically-implanted materials (e.g. inaccessible tumor
sites, infection), injectable scaffolds are being developed and studied to create local
immunogenic treatments on par with implantable scaffolds. Injectable scaffolds offer many
advantages over implantable scaffolds, particularly the ability to access hard-to-reach
tumors that implantable scaffolds cannot reach. Some tumors are inoperable, so implanting
a scaffold to aid in an immunotherapy cancer treatment would be hindered. However,
injectable scaffolds could be placed close to inoperable tumor sites to enhance cancer
treatment. Injectable scaffolds have been developed using materials including alginate [49],
gelatin

[50]

, and mesoporous silica rods (MSRs) [26,51], among other materials. Injectable

scaffold materials are injected as a solution before rapidly assembling into a 3D matrix in
vivo that can recruit and activate immune cells or act as immunomodulatory drug
17

reservoirs. For example, injectable MSRs with a high aspect ratio can spontaneously form
a macroporous 3D scaffold to allow for immune cell recruitment and modulation. In a study
done by Kim and colleagues, injectable high-aspect-ratio MSRs were developed to
assemble in vivo and recruit host immune cells by releasing GM-CSF into the surrounding
tissue

[26]

. After recruitment, the immune cells, primarily DCs, could be matured using

CpG-ODN and protein antigens. Kim and colleagues assessed the ability of the MSR
system to induce antigen-specific adaptive immune responses. The MSR loaded with OVA,
GM-CSF, and CpG-ODN produced strong titers for sera anti-OVA IgG 2a and IgG1 which
corresponds to strong TH1 and TH2 responses, respectively. The injectable MSR system the
researchers developed performed better than the control bolus model containing only the
vaccine or OVA and showed improved humoral and adaptive immune responses. To
further solidify the effectiveness of the purposed MSR vaccine system, Kim and colleagues
conducted a study to investigate the ability of the delivery system to produce an antitumor
immune response (Figure 5). Mice were vaccinated with MSR vaccines then later
inoculated with EG7.OVA lymphoma cells. Mice vaccinated using MSR scaffolds loaded
with OVA, GM-CSF, and CpG-ODN had tumors with significantly smaller volumes
compared to bolus injection of the vaccine (P < 0.05), MSR scaffolds loaded with OVA
only (P < 0.01), and blank MSR scaffolds (P < 0.001).
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Figure 5: Prophylactic cancer vaccine study using injectable, spontaneously forming MSR scaffolds.
C57BL/6J mice received MSR vaccine and were challenged 10 days post-vaccination with EG7.OVA
lymphoma cells in the back of the neck. EG7.OVA tumor volume (A) and survival rate (B) were monitored
after tumor inoculation. In graph A, tumor volumes between treatment groups were compared on days 21,
23, and 25. Error bars represent mean ± s.e.m. (n = 10). Data analyzed using Student’s t-test (*P < 0.05, **P
< 0.01, ***P < 0.001). Figure adapted from Ref [26].

Scaffolds: Design Parameters
Like hydrogels, modifying different design parameters of scaffolds can change the
physical properties of the matrix, impact diffusivity of immunomodulatory factors to
surrounding tissue, and bioreactivity. The physical properties of the scaffold are principally
impacted by the choice of polymer and the fabrication process. Polymers have a specific
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set of physical properties that are important in determining the structural stability of the
scaffold when placed within the human body. The scaffold must be able to retain its form
and avoid a premature collapse of the 3D matrix. In addition to considering the mechanical
properties of the scaffold, designers also must consider the diffusive properties of the
matrix. Like hydrogels, diffusion is an important factor for scaffolds in aiding immune cell
recruitment and survival as well as controlled drug release. The diffusion coefficient, as
well as the drug loading capability, of the scaffold is dependent on the porosity of the
matrix. The pore size of scaffolds depends highly on the fabrication method used. For
instance, one method to create a 3D matrix in the scaffold is by sparging air or carbon
dioxide as the scaffold sets. This creates bubbles/pores in the scaffold to allow for diffusion
and drug loading

[52]

. Other variations of this fabrication exist including gas generation

from the crosslinking process. One of the simplest and oldest methods of fabrication is
particulate leaching, or salt leaching [52]. In this method, salt or other porogens are poured
into a mold followed by the polymer solution. Once the solvent evaporates, the salt is
leached away with water leaving pores in the scaffold. A more controllable fabrication
method is the use of 3D printing to create a crosslinking lattice. In the study done by Yang
et. al., the PFN scaffold was fabricated using an E-jet 3D printer

[48]

. The porosity of the

scaffolds impacts the drug release profile of the delivery device. Researchers created
various scaffolds with different degrees of porosity by using different aperture sizes. Their
studied showed that as aperture size increased the porosity of the scaffold increased.
Scaffolds can be engineered by many approaches to improve immune cell
recruitment and spatiotemporal drug release. One such route is to modify scaffold porosity.
Injectable high-aspect-ratio MSRs nonspecifically assemble to form 3D structures
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containing interparticle spaces, or pores. For example, researchers used MSRs with a
hexagonal mesoporous structure and upon injection with a pore-directing agent, Pluronic ®
P-123, scaffolds with a 3D microenvironment were produced

[26]

. These researchers also

tested the effect of mesopores and macropores in immune cell recruitment by looking at
cell recruitment in 2 materials: a pore-filled silica microrod with similar qualities to MSRs
but lacking the mesoporosity of pristine MSRs and a pressed MSR that preserved the
mesopores but lacked macropores. Equal masses of the pore-filled MSRs, pressed MSRs,
and untampered MSRs were injected into mice and the number of host cells recruited into
the scaffold was analyzed on day 3. The pristine MSRs recruited approximately 2.4 * 10 6
cells which was significantly higher than the pore-filled and pressed MSRs (P < 0.05).
When comparing pore-filled MSRs to pressed MSRs, pore-filled MSRs recruited
approximately 0.4 * 106 more cells than pressed MSRs.

This data indicates that

interparticle macropores were vital in cell recruitment into the scaffold.
Another way to impact the efficacy of scaffolds is through surface modification.
Some synthetic polymers used as the basis of the scaffold have poor bioreactivity which
can hinder cell recruitment and activation; however, this can be changed through surface
modification. Aileen Li et. al. conducted a study analyzing the effect of surface
modification of MSR scaffolds on immune cell recruitment and programming

[27]

. They

modified the scaffold with PEG, PEG-RGD (integrin-binding ligand Arg-Gly-Asp), and
PEG-RDG (Arg-Asp-Gly) groups. Mice received subcutaneous injections of either
unmodified MSRs or one of the surface-modified MSRs. On day 5, the scaffolds were
explanted and analyzed. The total cell content of PEG modified MSRs were significantly
higher than the cell content of unmodified MSRs (P < 0.05). The total number of cells
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infiltrating PEG-modified MSRs was 10 times greater than unmodified MSRs and 4 times
greater than PEG-RGD MSRs or PEG-RDG MSRs. Next, the type of immune cells that
infiltrated that scaffold was analyzed. PEG MSRs contained a significantly lower mean
percentage of DCs (< 1%) compared to unmodified MSRs (~4%), but the total number of
DCs was not significantly different between the MSR scaffolds. A majority of the
infiltrating immune cells were myeloid cells/neutrophils. PEG modified MSR scaffolds
had a mean percentage of approximately 75%, significantly higher than the mean
percentage of myeloid cells/neutrophils that infiltrated the unmodified MSRs (~63%),
PEG-RGD-modified MSRs ( ~53%), and PEG-RDG-modified MSRs (~ 53%) (P < 0.05).
MSRs modified using PEG displayed increased inflammatory responses which in turn
increased immune cell recruitment. On the other hand, scaffolds modified with PEG-RGD
and PEG-RDG showed decrease immune responses likely due to a hindrance in
interactions between PEG and components of the ECM.

Microparticles
Microparticles are substantially smaller than hydrogels and scaffolds and are
normally used to encapsulate various immunomodulatory agents including immunotherapy
drugs and cancer vaccines. Microparticles typically range from ~1 μm to 50 μm in
diameter. The large size of microparticles impacts particle diffusion and interaction with
host cells. For instance, microparticles are taken up by immune cells, specifically APCs,
via phagocytosis while smaller delivery systems such as nanoparticles can be taken up via
endocytosis and micropinocytosis

[53]

. These particles can be loaded with cancer antigens

and/or immunomodulatory drugs and tagged with antibodies to target immune cells. When
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used as a cancer vaccine delivery system, microparticles protect the antigen from
degradation normally associated with a bolus injection and are a good platform for
synergistic combination therapies to enhance an antitumor response. Microparticles can
serve both as local and systemic immunomodulatory biomaterials, but systemic
applications are limited due to the large relative size of microparticles, i.e. they are too
large to circulate. As a local immunomodulatory biomaterial, microparticles reside in the
target/injection site to deliver therapeutics in a controlled, often sustained manner using a
variety of drug release mechanisms (Figure 6). In this context, microparticles can be used
alone or in conjunction with hydrogels and scaffolds. For instance, Davoodi et. al.
formulated a treatment system that utilized a core-shell polymeric microparticle
encapsulating cisplatin and paclitaxel embedded in an injectable hydrogel to create a novel
localized delivery system to treat triple negative breast cancer

[54]

. Microparticles provide

a modifiable platform to optimize local drug delivery of immunotherapeutic.
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Figure 6: Various release mechanisms of microparticle systems. Active pharmaceutical ingredient (API).
Figure adapted from Ref [79].

Microparticles: Types of Microparticles and Their Applications
Microparticles can be fabricated using a variety of methods, including organismderived, natural, and synthetic microparticles

[12]

. Organism-derived microparticles are

released by cells, collected, and purified into the final material. Exosomes – extracellular
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vesicles with cellular origin – are an example of organism-derived microparticles. Tumors
release exosomes, containing tumor-specific antigens, when exposed to an external
stimulus that can be used as a vaccine. For example, Zhao et. al. created tumor
microparticles (T-MPs) by exposing B16F10 tumor cells to UV radiation [28]. After release,
the exosomes were loaded with nano-sized Fe3O4 and CpG-loaded liposomes were attached
to the surface of exosomes. To assess the capabilities of the Fe 3O4/T-MPs-CpG/Lipo
vaccine to produce an antitumor response, the researchers conducted a prophylactic study
using the B16F10 melanoma tumor model (Figure 7). Mice were vaccinated on days 1, 2,
and 7 then received an inoculation of B16F10 cells on day 8. 85.7% of the mice vaccinated
with the Fe3O4/T-MPs-CpG/Lipo vaccine formulation remained tumor-free by the end of
the study.
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Figure 7: Murine B16F10 melanoma prophylactic study using Fe3O4/T-MPs-CpG/Lipo vaccine. C57BL/6
mice were vaccinated on days 1, 2, and 7 followed by melanoma cell inoculation on day 8 (A). Average
tumor growth curves (B) and the survival rate (C) were calculated during the experimental time. Error bars
represent mean ± SD (n = 7). Data in graph B was analyzed using two-way ANOVA with the Bonferroni’s
multiple comparison post-test and data in graph C was analyzed using the log-rank test (*P < 0.05, **P <
0.01, ***P < 0.001). Figure adapted from Ref [28].

On day 20, tumor tissue was extracted and analyzed to assess the immunogenicity of the
tumor. To determine the switch from a “cold” tumor to a “hot” tumor, researchers looked
at a phenotypic switch in macrophages from pro-cancer M2 macrophages to anti-cancer
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M1 macrophages. Vaccination with the Fe3O4/T-MPs-CpG/Lipo formulation enhanced M1
macrophage surface marker expression compared to an empty control and the T-MPsCpG/Lipo vaccine. The researchers also analyzed cell suspensions from the lymph nodes
and spleen to further demonstrate the ability of the Fe 3O4/T-MPs-CpG/Lipo vaccine to
switch macrophages to an M1 phenotype. Based on a one-way ANOVA with Bonferroni’s
post-test, the percent of M1 macrophages was significantly higher in mice vaccinated with
the Fe3O4/T-MPs-CpG/Lipo vaccine compared to an empty control (P < 0.001) and the TMPs-CpG/Lipo vaccine (P < 0.01).

By creating this newly modified tumor

exosome/microparticle, the researchers were able to elicit a strong immune response that
increased the immunogenicity of the TME and inhibited tumor growth.
Natural polymer-based microparticles, such as alginate and chitosan, are
biocompatible and readily tunable to allow for variable drug release mechanisms. In an
early study by Lin-Shu Liu et. al., porous microspheres formed from alginate and chitosan
were loaded with IL-2 to study the drug release profile and bioactivity of the released
cytokine overtime

[29]

. The researchers conducted a protein release study with 3

formulations of alginate microspheres using CaCl 2, chitosan, and polylysine. These
alginate microspheres were loaded with different amounts of proteins including albumin,
bovine-fluorescein isothiocyanate (FITC-BSA), and IL-2. With a FITC-BSA protein
loading of 10 wt%, alginate/chitosan microspheres released 45% of the payload within 6
hrs compared to nearly 100% release by alginate/CaCl 2 microspheres and 75% release by
alginate/polylysine. Alginate/chitosan microspheres steadily released FITC-BSA over 4
days compared to the rapid release of the protein from the other microspheres within 2
days. Based on this preliminary data, alginate/chitosan microspheres showed promising
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drug release profiles, so the researchers assessed release of IL-2 from these materials. Over
a period of 5 days, alginate/chitosan microspheres steadily released 100% of the loaded IL2. After investigating the protein release profile of the alginate microspheres, the
researchers assessed the ability of the alginate/chitosan microspheres to activate cytotoxic
T lymphocytes. In this experiment, either microspheres loaded with IL-2 or free IL-2 were
added to a cell culture of human lung squamous carcinoma SQ-5 cells and peripheral blood
mononuclear monocytes. Activated lymphocytes were isolated from the culture at 1 week
post treatment and 1 month post treatment to assess T cell activation over both short-term
and long-term culture periods. After 1 week, both the microsphere delivery system and free
administration of IL-2 yielded 4.5 * 107 activated T cells. After the 1-month culture period,
the microsphere system yielded 80 * 107 activated T cells compared to 47 * 107 activated
T cells by free IL-2. Alginate/chitosan microspheres steadily released IL-2 over time and
effectively generated more activated T cells compared to free IL-2 during longer culture
periods.
Synthetic polymer-based microparticles are highly customizable and readily
available for use. In a study by Rahimian et. al., poly (lactic-co-hydroxymethyl-glycolic
acid) (pLHMGA) microparticles were loaded with either antiCD40 or antiCTLA-4
immunomodulatory antibodies

[30]

. During an in vitro antibody release study, the

microparticle initially released about 20% of the antibody payloads followed by a sustained
release of antiCD40 or antiCTLA-4 reaching 80% drug release by day 30. The researchers
also investigated the therapeutic efficacy of the microparticles, compared to incomplete
Freund’s adjuvant (IFA), by treating mice inoculated with MC-38 cells, a colon carcinoma
tumor model, when the tumor became palpable (Figure 8). 50% of the mice survived that
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received antiCD40 antibody treatment from either IFA or from the microparticles
compared to 10 % survival in untreated mice. A similar trend occurs in mice treated with
antiCTLA-4 antibody treatment. 40% of the mice treated using microparticles survived and
30 % of the mice treated with using IFA survived. Compared to untreated mice,
significantly more mice survived after treatment with antiCD40 (P < 0.001) and antiCTLA4 (P < 0.01). These microparticles increased the survival rate of mice inoculated with MC38 tumors that was comparable to common IFA formulations. In sum, polymer chemistry
and source play integral roles in determining the application of microparticles in cancer
immunotherapy

Figure 8: Therapeutic efficacy of antiCD40 and antiCTLA-4 microparticle formulation against MC-38 tumor
cells. Kaplan-Meier plots presenting the survival proportions of tumor bearing mice treated with different
microparticle formulations containing antiCD40 (A) and antiCTLA-4 (B). Data from two experiments (n =
14-18). Data analyzed using log-rank test (*P < 0.05, **P < 0.01, ***P < 0.001). Figure adapted from Ref
[30].
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Microparticles: Design Considerations
The application of the microparticle greatly influences which design parameters to
consider during fabrication. After injection, microparticles will either interact with immune
cells, specifically phagocytes and APCs, or act as an immunomodulatory agent reservoir,
providing controlled and sustained drug release. Microparticles that act as cancer vaccines
or tumor antigen reservoirs should be taken in by APCs through phagocytosis. Once inside
the APC, the microparticle is broken down in an endosome and loads freed antigen to Major
histocompatibility complex (MHC) I and II to start the maturation process for an antitumor
response. In a study conducted by Foged et. al., the role of particle size and surface charge
in microparticle uptake by human DCs was investigated

[31]

. The researchers used

polystyrene spheres with diameters of 0.1, 0.5, 1.0, and 4.5 μm to model microparticles.
To assess the interaction between microparticles and dendritic cells (DCs), microparticles
of various diameters were incubated for 24 hours with DCs and analyzed by flow cytometry
to quantify the amount of double positive cells (indicative of microparticles bound to the
surface of the DCs). From the flow cytometry analysis, less than 5% of DCs bonded with
microparticles with a diameter of 4.5 μm, 10% of the DCs interacted with 1.0 μm
microparticles, 30% of the DCs bonded with 0.5 μm microparticles, and 60% associated
with 0.1 μm microparticles. As particle size decreased, the number of polystyrene spheres
bound to DCs, thus potentially endocytosed, increased. In the case of surface charge,
different polyaminoacids/proteins were conjugated to the surface of polystyrene spheres
with a diameter of 1 and 0.1 μm. The negatively charged particles interacted less with DCs
compared to the particles with a positive surface charge. Based on their results, the
researchers saw that surface charge played a bigger role in DC interaction for large particles
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suggesting that modifying larger particles to have a positive charge could enhance DC
uptake. On the other hand, microparticles that provide sustained release of
immunomodulatory agents should avoid being internalized by phagocytes. For this reason,
many physicochemical and mechanical properties can be considered to discourage
microparticle clearance by phagocytes. A review paper to note by Moon et. al. provides an
in-depth review of the impact of particle shape and mechanical properties on phagocyte
interactions

[32]

. Microparticles are a valuable local immunomodulatory biomaterial with

broad applications due to their simplicity and elegance.
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Systemic Immunomodulatory Biomaterials
Systemic administration of immunomodulatory drugs is a promising approach for
the treatment of metastatic cancers that has spread to distant sites throughout the body as
well as the treatment of primary tumors. Accordingly, the U.S. Food and Drug
Administration has approved many immunotherapy drugs to treat metastatic cancer, e.g.
interferons, interleukins, toll-like receptor agonists, and immune checkpoint inhibitors
[3,5,55-56]

. Even though these immunotherapies have gained FDA approval, systemic

administration

of

the

drugs

have

multiple

drawbacks

[55-56]

. The

dose

immunomodulatory drugs given systemically is limited by concerns about toxicity

of
[57]

.

Additionally, large portions of the systemically administered drugs fail to reach the target
site, instead biodistributing to other organs, limiting on-target efficacy and increasing offtarget toxicity

[58-59]

. Immunomodulatory drugs are rapidly excreted, degraded as they

circulate, and accumulate at off-target sites

[59]

. To address the poor natural

pharmacokinetics and biodistribution of many immunotherapeutic drugs, numerous
immunomodulatory biomaterials have been developed for systemic delivery. Here, we
focus our attention on two major classes of systemic delivery materials: nanoparticles and
drug conjugates.
Nanoparticle technology has been widely studied for the delivery of
immunomodulatory drugs. Nanoparticles contain many customizable features that can be
modified to: target specific immune cells or cancer cells, degrade at a pre-programmed or
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adjustable/responsive rate, protect the immunomodulatory drug in circulation, and improve
biodistribution to lymph nodes and/or tumors. Nanoparticles are an especially promising
delivery system because 1) they can leverage the enhanced permeability and retention
(EPR) effect to target tumors

[60-61]

and 2) recent reports show efficient accumulation of

nanoparticles in tumor-associated leukocytes [62-63].
Drug conjugation modifies the immunomodulatory drug itself to improve
pharmacokinetics and biodistribution. Immunomodulatory drugs can be conjugated to
monoclonal antibodies to target the drug to key receptors that are predominantly expressed
on leukocytes or cancerous cells. This targeting strategy reduces off-target accumulation
and can thus reduce systemic toxicity that results from off-target effects

[59]

.

Immunomodulatory drugs can also be conjugated to synthetic polymers that serve to
protect the drug from the harsh environment of the circulatory system as well as enhance
the pharmacokinetics of the drug (i.e. increase the circulation half-life) [59]. By protecting
immunomodulatory drugs using nanoparticles or conjugation methods, researchers can
improve the efficacy of the drug, reduce dose-limiting toxicities, and create a delivery
platform that is tunable to a variety of applications.

Nanoparticles
Due to the systemic administration of nanoparticles, they are able to interact with a
wide range of targets and elicit multifaceted immune responses

[9,12,64]

. For instance,

nanoparticles can be leveraged to guide biodistribution to regional lymph nodes
target immunotherapeutics to a primary tumor
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[36,61]

[65]

and

. A central goal in cancer

immunotherapy is to activate T-cells to seek and eliminate both local and metastatic
cancerous cells. To achieve this goal, nanoparticles are used to deliver cancer vaccines,
antigens, and adjuvants to APCs, deliver agonists to T-cells directly, imitate APCs to
initiate T-cell proliferation, and deliver immune checkpoint inhibitors [33]. In addition to Tcell activation, nanoparticles protect immunotherapy drugs from degradation in the blood
and enhance treatment by prolonging circulation time by focusing the drug biodistribution
to specific targets [59]. Importantly, a wide range of nanoparticles have been developed that
are either approved by the FDA or currently progressing through clinical trials

[36]

. By

continued improvement in our understanding of tumor immunobiology, advancements in
materials chemistry and nanotechnology, and effective interdisciplinary collaboration
between immunologists and biomedical engineers, the development of more FDAapproved products that can have a major impact on cancer immunotherapy are underway.
Immunotherapeutic drugs face a wide range of obstacles, such as cellular uptake
and trafficking barriers, depending upon the type of drug (e.g. small molecule, antibody,
nucleic acid) and intracellular destination (Figure 9). Upon encountering an appropriate
APC, nanoparticles should trigger internalization into the targeted cell. Upon
internalization, fate of the nanoparticles and accompanying immunotherapeutic drugs can
be tuned to suit the intended application. For instance, immunotherapies for endosomal
targets (e.g. TLR7/8 agonists and antigens for MHC-II) necessitate cell uptake via
endocytosis but do not require endosomal escape, whereas immunotherapies for cytosolic
targets (e.g. 5’pppRNA and mRNA vaccines) require both cell uptake and efficient
endosomal escape. In a study done by Oberli et al.[34], lipid nanoparticles were used to
transfect APCs with an mRNA vaccine coding for two melanoma self-antigens: tyrosinase34

related protein 2 (Trp2) and glycoprotein 100 (gp100) with a point mutation. Vaccination
with the lipid nanoparticles greatly increased the number of transfected APCs and
increased CD8 T cell proliferation thus increasing the survival rate of mice with B16F10
tumors. By using a lipid nanoparticle, the researchers were able to effectively address the
delivery challenges of using mRNA vaccines. The lipid nanoparticles employed by this
group consisted of 5 components: an ionizable lipid, a phospholipid, cholesterol, PEG
containing lipids, and an additive for mRNA vaccine delivery. Each of these components
aid in the processes of biodistribution, cellular uptake, and endosomal escape. The
ionizable lipid becomes positively charged at lower pH to aid in conjugation to mRNA and
the positive charge aids in cellular uptake and endosomal escape. By incorporating
phospholipids and cholesterol into the lipid nanoparticle, researchers help stabilize the
particle and help with endosomal escape. By using PEG-lipid conjugates in the
nanoparticle, the researchers discourage nanoparticle aggregation thus aiding in
biodistribution.
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Figure 9: Schematic of cell targeted delivery of immunotherapeutic agents using nanoparticles. Composed
of three steps: i) the nanoparticle binds to specific receptors of the cell, ii) endocytic uptake of the nanoparticle
through receptor-mediated endocytosis, and iii) immunotherapeutic agent release via endosomal escape.
Figure adapted from Ref [39].

In another study done by Xu et. al., researchers used a nanoparticle composed of a
calcium phosphate (CaP) core and an asymmetric lipid bilayer (lipid-calcium-phosphate
(LCP) nanoparticle) to deliver a peptide vaccine of Trp2 to mouse models of melanoma
(B16F10) [35]. The goal of the study was to elicit MHC I-restricted cytotoxic T-lymphocyte
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responses to eradicate B16F10 tumors. In order for the peptide to be effective in creating
an immune response, the nanoparticle has to deliver the vaccine to the cytosol of the APC.
To achieve this goal, Xu and colleagues modified the surface of the nanoparticle with
mannose to bind to mannose receptors of APCs and aid in cellular uptake. Additionally,
LCP nanoparticles have two mechanisms of endosomal escape depending on the number
of nanoparticles taken in by the APC

[66]

. If large quantities of LCP nanoparticles are

endocytosed, endosomal escape occurs due to an increase in osmotic pressure in the acidic
environment of the endosome that results in the dissolution of the CaP core. If smaller
quantities of LCP nanoparticles are endocytosed, endosomal escape results from the
formation of ion pairs between the cationic lipids in the asymmetric bilayer,
dioleoylphosphatydic acid (DOTAP), and negatively charged groups in the endosomal
membrane. On the other hand, some nanoparticles do not have to be endocytosed by APCs
to elicit an immune response. For example, researchers can conjugate MHC and antigen
complexes to the surface of nanoparticles to create artificial APCs that can activate T cells
[67]

. By following similar design processes, nanoparticles can be synthesized that efficiently

deliver immunotherapeutics to a variety of intracellular targets; endosomal, cytosolic, and
otherwise.

Nanoparticles: Design Considerations
Nanoparticles can be fabricated using a variety of methods; however, there are key
design parameters that must be considered in order to create an effective delivery system.
The size of nanoparticles plays a key role in nanoparticle accumulation at tumor sites and
clearance by phagocytes. Though the EPR effect is variable and mechanisms to better
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understand nanoparticle accumulation in tumors are being investigated, tumors that contain
leaky vasculature and impaired lymphatic drainage allow circulating nanoparticles to
preferentially infiltrate the tumor and avoid clearance from the tumor site. One study of
note was conducted by Perrault et. al. to systematically study how particle size (10-100
nm) influenced the pharmacokinetics of nanoparticles

[37]

. One of the experiments

conducted by the researchers investigated the tumor accumulation of nanoparticles with
varying sizes (20 nm, 40 nm, 60 nm, 80 nm, and 100 nm). Each size bracket showed
different levels of accumulation in the tumor site; however, the researchers saw no clear
trend between particle size and tumor accumulation. In the researchers’ model, the lack of
correlation between particle size and tumor site accumulation should be reflected by a
dependence on blood/circulation half-life over time. After doing a regression analysis, the
researchers found that this phenomenon was only significant for particle sizes ranging from
40-100 nm (P < 0.02). This suggests that the size of smaller nanoparticles may affect tumor
accumulation. To investigate this further, the researchers conducted another regression
analysis that considered volumetric size of the nanoparticles (nm 3) and half-life. This
analysis revealed a significant relationship in particle sizes ranging from 20 nm to 100 nm
diameter in relation to half-life (P < 0.015). This regression analysis showed that the
accumulation of nanoparticles around 20 nm depends on its size and half-life. On the other
hand, particles ranging from 40-100 nm depends almost entirely on circulation half-life
indicating a possible route to modify tumor accumulation by modifying pharmacokinetic
parameters. Another important design factor brought to light by the study is the impact of
size on the permeation of nanoparticles. Generally, as particle size increased, the area of
permeation within tumors became smaller. In summation, these results show that
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nanoparticle size profoundly impacts the amount of nanoparticle accumulation and
homogeneity in the tumor site. Thus, researchers must determine the acceptable size range
for nanoparticles to optimize accumulation and permeation for their particular application
– though for most cases nanoparticles in smaller size ranges (~20-50 nm) appear most
suitable.
Other key design considerations include the material of the particle, surface charge,
and degradation mechanism

[38,39]

. For instance, nanoparticles composed of PEG are

generally non-toxic and non-immunogenic, whereas poly(beta-amino esters) becomes
immunogenic as they are degraded over time [76]. Surface charge is an important parameter
with regards to cellular uptake and circulation time. Nanoparticles with a positivelycharged surface have a higher rate of cellular uptake while neutral and slightly negativelycharged surfaces reduce cellular uptake. Due to the increased cellular uptake of positivelycharged nanoparticles, in addition to rapid protein adsorption and aggregation, these
particles generally have very short circulation times. For this reason, charged materials are
often coated with materials like PEG to shield surface charge, increase biocompatibility,
and prevent particle clearance by the MPS system. The degradation mechanism and drug
release trigger can be modified to suit a wide range of applications. Some of these triggers
include tumor hypoxia, low pH of endosomes and TME, tumor-specific enzymes, and
oxidative stress. These triggers cause biodegradation of the nanoparticle material while
also enabling a mechanism for drug release from the particles. For further analysis, please
see the extensive review on linker chemistry design and nanoparticle drug release by Wong
and Choi [39].
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Nanoparticles: Types of nanoparticles and Their Applications
Nanoparticles are one of the most customizable biomaterials/delivery systems used
in research. They can be created from a range of polymers and biological agents including
synthetic polymers like PEG, lipids/lipid-like materials, natural polymers like hyaluronic
acid, and inorganic metals like gold

[64]

. Similar to composite hydrogels and scaffolds,

hybrid nanoparticles can be produced by combining different material classes into
composites to leverage positive characteristics of each material. Researchers have
engineered many types of nanoparticles including silica nanoparticles, dendrimers, carbon
nanoparticles, ceramic nanoparticles, etc. [68,69]. The three types of nanoparticles discussed
here are lipid-based, synthetic polymer-based, and natural polymer-based.
Lipid-based nanoparticles and liposomes are primarily composed of lipids and
follow the design criteria of vesicles. The lipid-based nanoparticles can be composed of an
ionizable lipid, phospholipids, cholesterol, PEG-lipids, and additives to aid in drug/vaccine
delivery. Liposomes are primarily composed of either natural or synthetic lipids. They can
have single or multiple lipid bilayers with an aqueous core to house both hydrophobic and
hydrophilic immunomodulatory agents/drugs. A key advantage of lipid nanoparticles is the
ease of conjugating ligands to the surface of the particle. The conjugation of ligands gives
nanoparticles the ability to target key immune cells and encourage cellular uptake. In a
study done by Zhang et. al., the surface of PEGylated liposomes were coated with IL-2
agonists and anti-CD137 ligands to stimulate the proliferation of cytotoxic T lymphocytes
and natural killer (NK) cells as well as act as a co-stimulatory signal for T cell activation
[40]

. The researchers first assessed the effectiveness of a combinational treatment with anti-

CD137 and IL-2-Fc, a fusion of the Fc domain to IL-2 to prolong circulation half-life,
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against the B16F10 melanoma model. Mice with established B16F10 tumors received
systemic injections of 20 μg of IL-2-Fc and 100 μg of anti-CD137 every 2 days for a total
of 3 doses. The mice treated with anti-CD137/IL-2-Fc had smaller average tumor sizes
compared to untreated mice; however, the mice experience severe systemic toxicity along
with rapid weight loss that ultimately led to death by the third injection. Additionally, using
a longer time interval between doses (1 week) did not mitigate systemic toxicity in the
mice. On the other hand, lowering the doses decreased the level of toxicity but it also
reduced the treatments effectiveness against B16F10 melanomas. Treatment with antiCD137/IL-2-Fc caused a dose-dependent systemic cytokine storm resulting in heightened
cytokine levels. By conjugating these immune agonists to the surface of liposomes, the
researchers were able to eliminate the toxic side effects, indicated by rapid weight loss and
elevated cytokine levels, associated with systemic administration of IL-2 and CD137
antibodies. As seen in Figure 10, mice treated with the modified liposome had significantly
delayed tumor growth compared to an isotype control liposome (Lipo-IgG) and
systemically administered anti-CD137/IL-2-Fc (P < 0.05) and maintained constant body
weight which signifies the absence of systemic toxicity. Furthermore, mice that were
treated with the immunoliposome had a significantly higher survival percent compared to
the untreated group, the free IL-2-Fc/αCD137 treatment group, and the liposome control
group (P < 0.001) For more information, a detailed review on liposomes and lipid
nanoparticle drug delivery systems was written by Kraft and his colleagues
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[41]

.

Figure 10: Therapeutic efficacy of immunoliposome IL-2-Fc/αCD137 therapy. Groups of C57BL/6 mice
were inoculated with B16F10 melanoma cells followed by systemic injections of treatment groups on days
8, 10, 12, and 14 post inoculation. Data shows mean tumor sizes (A), relative body weight indicative of
systemic toxicity (B), and overall survival of mice (C). Error bars represent mean ± s.e.m. (n = 6-7 per group).
Data analyzed using two-tailed Student’s t-test (*P < 0.0005, ***P < 0.001). Figure adapted from Ref [40].

One of the most common materials used for fabricating nanoparticles are synthetic
polymers due to their ease and affordability of synthesis, wide availability, and
customizability. Synthetic nanoparticles made from materials like PLGA and PEG allow
for a controlled release of immunomodulatory agents to prolong the effect of the drug while
minimizing potential side effects. Synthetic nanoparticles also allow for a modifiable
platform to control pharmacokinetic parameters, control biodistribution, and control
targeting specificity. In a study done by Schmid et. al., nanoparticles made from FDAapproved PLGA and PEG were designed to target T cells that commonly infiltrate the TME
and “hitchhike” to the tumor site before releasing SD-208, a TGFβRI kinase inhibitor [42].
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TGFβ plays a role in immunosuppression in the TME [77], so by administering SD-208 the
researchers hope to reverse the immunosuppressive TME. To establish the T-cell targeting
system, the researchers conjugated anti-PD-1 antibody fragments to the surface of the
PLGA/PEG nanoparticle to target CD8+ T-cells that were PD-1+ because these T-cells
frequently infiltrated the tumor site

[78]

. To assess the therapeutic potential of the

nanoparticle delivery system, the researchers conducted in vivo studies using the MC38
colorectal cancer model (Figure 11). Mice were inoculated with MC38 tumor cells. After
5 days, mice were administered the nanoparticle formulation or free drugs (20μg anti-PD1 and 40μg SD-208) and received subsequent doses every other day up to a total of 10
doses. Free administration of the drugs had no reductive effects on tumor growth, but tumor
growth was delayed when the SD-208 was delivered using the PD-1 targeting
nanoparticles. Additionally, the survival rate of mice treated with this nanoparticle
formulation was significantly higher compared to the other treatment groups (P < 0.001).
However, tumor growth in mice treated with the forementioned nanoparticle formulation
continued to progress until it reached a tumor volume of 2000 mm 3, like the untreated and
free drug groups but delayed by 7 days. Even though immune evasion prevailed in this
tumor model, the nanoparticle formulation was able to delay growth and offers a platform
for further modification to create a synergistic therapy that will utilize the niche of hindered
tumor growth.
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Figure 11: Therapeutic effect of targeted delivery of SD-208 (a TGFβR1 inhibitor) using anti-PD-1 tagged
nanoparticles. C57BL/6 mice were inoculated with MC38 cells and treatment with nanoparticle formulations
or free drugs occurred 5 days post inoculation. Mice received subsequent doses every other day up to a
maximum of 10 doses. Tumor volume (A) and mice survival (B) was monitored over course of study. Error
bars represent mean ± s.e.m. (n = 6). Data analyzed using Mantel-Cox test (***P < 0.001). Figure adapted
from Ref [78].

In a subsequent study done by the researchers to repurpose the nanoparticle targeting
system, the researchers considered the possibility of eliciting an inflammatory response in
the TME by delivering a Toll-like receptor (TLR) 7/8 agonist, R848, to make the MC38
tumor more sensitive to immune checkpoint blockade therapy. The researchers conducted
another in vivo study using R848 instead of SD-208 (Figure 12). Mice were inoculated
with MC38 tumor cells and received doses on day 5 followed by doses every other day for
a maximum of 10 doses. The delivery of R848 using PD-1 targeted nanoparticles
significantly delayed tumor growth compared to untreated mice and mice that received free
drugs (P < 0.05) and significantly more of the mice treated with the nanoparticles survived
at the end of the study (P < 0.001). Synthetic nanoparticles allow researchers to easily
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customize the surface and structure of the nanoparticle to optimize immunotherapeutic
drug delivery.

Figure 12: Therapeutic effect of targeted delivery of R848 (a TLR7/8 agonist) and sensitization of tumors to
PD-1 blockade. C57BL/6 mice were inoculated with MC38 tumor cells followed by nanoparticle or free drug
treatment on day 5 and every other day for a total of 10 doses. Tumor volume and animal survival were
monitored to assess efficacy (A,B). For graph C-D, nanoparticle or free drug treatment were administered on
days 5, 7, and 9 after tumor inoculation to inflame the tumor. Mice were then treated on days 11, 14, and 17
with anti-PD-1 antibody through intraperitoneal injection. Tumor volume and animal survival were
monitored to assess efficacy (C,D). Error bars represent mean ± s.e.m. (n = 6-7). Data analyzed using MantelCox test (*P < 0.05, ***P < 0.001). Figure adapted from Ref [78].

Natural polymeric nanoparticles are fabricated using polymers derived from natural
compounds. Natural compounds like HA, alginate, and chitosan have the advantage of
intrinsic biodegradability and biocompatibility. Drawbacks of using natural polymers
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include the variability between batches, potential for contamination, and difficulty to scale
synthesis. In a study done by Shi et. al., chitosan nanoparticles with mannose ligands
conjugated to the surface were loaded with whole tumor cell lysates (Man-CTS-TCL
nanoparticles) to act as a cancer vaccine that targets specific DCs

[70]

. One of the studies

conducted by the researchers assessed the prophylactic capabilities of the nanoparticle
vaccine formulation when challenged by an inoculation of 1*10 5 B16 tumor cells.
Vaccination using Man-CTS-TCL nanoparticles delayed tumor growth resulting in a mean
tumor volume less than 500 mm3 21 days after tumor cell inoculation. The tumor volume
in mice vaccinated with Man-CTS-TCL was significantly smaller than the tumor volume
in untreated mice (P < 0.05), in mice vaccinated only by using tumor cell lysates, in mice
treated with chitosan nanoparticles lacking mannose ligands (P < 0.05), and in mice treated
with chitosan nanoparticles with mannose ligands but lacking the tumor cell lysate payload
(P < 0.05). To further solidify the conclusion that Man-CTS-TCL nanoparticles are an
effective vaccination system, the researchers assessed the therapeutic effects of the
nanoparticles by vaccinating mice 7 days after receiving subcutaneous injections of B16
melanoma cells. Similar to the prophylactic study, Man-CTS-TCL nanoparticles
significantly inhibited B16 tumor growth compared to the untreated group (P < 0.05).
Nanoparticles made from natural polymers have intrinsic biodegradable and biocompatible
properties. Nanoparticles are a highly customizable drug delivery platform that can be used
to suit a variety of immunotherapeutic applications ranging from delivering cancer
vaccines to acting as artificial APCs.
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Drug Conjugates
Drug conjugation is a simple and effective modification strategy to improve the
efficacy of systemically administered immunomodulatory drugs. In drug conjugation,
immunomodulatory agents are simply conjugated to a targeting ligand, normally a
monoclonal antibody, or synthetic polymers to modify the pharmacokinetics of the
agents/drugs and minimize their side effects.

The two categories of drug conjugates

reviewed here are antibody-drug conjugates and polymer-drug conjugates. In cancer
immunotherapy, antibodies used alone can recognize specific antigens on or near the tumor
site to elicit a cytotoxic response, but the curative effects are limited unless the monoclonal
antibodies are modified through conjugation

[72]

. Antibody-drug conjugates utilize the

targeting capabilities of monoclonal antibodies and the cytotoxic/immunotherapeutic
effects of the conjugated drug [72,73]. The basic design of these conjugations consists of the
antibody, a linker, and the drug. Any of these three components can be modified to create
the best drug delivery system for the intended application

[43]

. Polymer-drug conjugation

allows researchers to modify the pharmacokinetics of immunotherapy drugs, protect the
drug from the environment, and allow for the conjugation of targeting moieties

[44]

. For

instance, conjugating immunotherapeutic or cytotoxic drugs to a synthetic polymer such as
PEG protects the drugs from enzymatic degradation and rapid clearance via the liver and
kidneys

[74,75]

. As a result, polymer-drug conjugates generally increase circulation time

compared to the parent drug. Polymer-drug conjugates depend on passive accumulation at
tumor sites and can be further modified with targeting ligands in order to bind specific
immune cell targets or cancer cells

[44]

. Many classes of polymer-drug conjugates exist

including polymers conjugated to biological proteins, small molecule drugs conjugated to
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a long polymeric chain, dendrimers, and others. These various conjugate arrangements can
elicit different pharmacokinetics and incorporate drug release mechanisms to create the
desired therapeutic effect

[44]

. Conjugating small-molecule drugs to polymer chains offers

several advantages such as improved solubility, increased drug stability, prolonged
circulation half-life, and altered biodistribution

[74]

. Conjugating polymers to biological

proteins shield the antigenic epitopes through steric hindrance as well as shields the protein
from circulating proteolytic enzymes and the MPS. The improved pharmacokinetics of
biological proteins reduces the dosage thus improving the safety of treatment. Today, many
drug conjugates have been approved by the FDA or are being tested in clinical trials [44,73].
Current advances in oncology research have primarily used antibody- and polymerdrug conjugation to deliver cytotoxic drugs; however, it is theoretically possible to replace
the drug component with common immunotherapies in future generations

[43,44]

. By

conjugating drugs to polymers and/or antibodies, researchers achieve a slower clearance
rate, prolonged drug circulation, and can potentially alleviate toxic side effects and the risk
of autoimmunity associated with systemic immunotherapy.
Polymer-Drug Conjugates: Design Considerations
The first rational model for “polymeric prodrugs”, or polymer-drug conjugates, was
created by Professor Helmut Ringsdorf in 1975

[45]

. These conjugates had five major

components: a solubilizer compound, the drug, the polymer backbone, spacers, and a
transport/targeting component. Any of these components can be modified to alter the
pharmacokinetics and biodistribution of the drugs. The polymer choice for the backbone
dictates which drugs can be conjugated, the biocompatibility of the drug conjugate,
biodegradation and clearance rate, and drug stability. One of the most important design
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considerations is the type of linker between the polymer and the drug. Through the
manipulation of linker chemistry, the release mechanism can be modified to focus drug at
the targeted site. This is especially important in preventing off-target drug release while in
circulation. These linkers can be pH-responsive, degradable by enzymes present at high
levels at tumor sites, or responsive to lysosomal enzymes. For example, Lv et al. conjugated
paclitaxel (PTX), a cancer therapeutic drug, to 3,3’-dithiodipropionic acid functionalized
methoxy poly(ethylene glycol)-b-poly(L-lysine) (mPEG-b-P(LL-DTPA)) to form a
polymer-PTX drug conjugate (P(L-SS-PTX))

[46]

. In this case, the conjugate linker is a

disulfide bond between the carboxyl groups of mPEG-b-P(LL-DTPA) and PTX which is
unstable in reductive and acidic environments. This mechanism allows for drug release
once the drug conjugate is taken into the cell’s endolysosomal pathway. This polymer-drug
conjugate can also be released in the extracellular matrix of the tumor due to the lower pH
and high concentrations of glutathione (GSH). During an in vitro drug release study, drug
release from P(L-SS-PTX) was slow, releasing less than 8% of the conjugated PTX, over
the time frame of the study (120 hours) when placed in an extracellular environment that
mimics the TME (pH of 7.4 with a concentration of 20 μM GSH). However, when the
concentration of GSH is increased to 10 mM, P(L-SS-PTX) rapidly releases more than
75% of the PTX over the 120-hour time frame of the study. To simulate the environment
of an endosome, the drug release profile was analyzed in an environment with a pH of 5.
P(L-SS-PTX) released approximately 50% of the PTX payload over 120 hours. Overall,
their drug design barely released any of the cytotoxic drug in neutral environmental
conditions but released a majority of the payload in the acidic and reductive environments.
Additionally, the researchers conducted an in vivo antitumor activity study using the B16F1
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melanoma tumor model to assess the therapeutic capabilities of P(L-SS-PTX) compared to
untreated mice, mice systemically administered PTX, and mice injected with P(L-PTX), a
similar polymer-PTX conjugate that lacks disulfide bonds (Figure 13). Mice injected with
P(L-SS-PTX) had an average tumor volume of approximately 250 mm 3 which was
significantly lower than the tumor volume of mice injected with P(L-PTX) (P < 0.01) and
systemically administered PTX (P < 0.001). The drug conjugate effectively hindered tumor
growth without toxic side effects, as indicated by a lack of weight loss, compared to free
systemic administration of paclitaxel and the drug conjugate lacking the disulfide linker.
This study did not focus on the use of an immunotherapy; however, it serves as a proof of
concept that can be applied to other immunotherapeutic agents.

Figure 13: In vivo anti-tumor efficacy of P(L-SS-PTX), a polymer-paclitaxel drug conjugate. C57BL/6 mice
were inoculated with B16F1 melanoma cells and tumor volume was allowed to grow until it achieved a tumor
volume of approximately 20-30 mm3. Mice were treated with (a) PBS, (b) free PTX, (c) P(L-PTX), or (d)
P(L-SS-PTX). Tumor volume (A) and body weight change (B) was assessed for treatment efficacy. Error
bars represent mean ± SD (n = 6). Data analyzed using Student’s t-test (*P < 0.05, **P < 0.001, #P < 0.001).
Figure adapted from Ref [46].
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Antibody-Drug Conjugates: Design Considerations
Antibody-drug conjugates have similar design considerations as polymer-drug
conjugates; however, antibodies provide a mechanism to target specific cell populations
such as tumor cells or tumor leukocytes via receptor-ligand binding. The basic design
components of antibody-drug conjugates are the antibody, the drug, and the linker. When
considering which antibody to use for the conjugation, researchers should consider an
antigen overexpressed on tumor cells (or tumor-associated leukocytes) but not expressed
on normal, healthy cells. In a review done by Perez et al., a list of target antigens for various
types of cancer is provided

[43]

. Once an antibody is chosen that will provide specific

binding, other properties must be considered such as antibody stability after conjugation,
in systemic transit, and at the site of targeted tumor or immune cells. Like polymer-drug
conjugates, the linker plays an important role in the stability and drug release of antibodydrug conjugates. These linker components can be sensitive to lysosomal enzymes, pHresponsive, or responsive to glutathione (a reducing agent). Some antibody-drug
conjugates utilized non-cleavable linkers. In these cases, the payload can only be released
once the conjugate is taken into the cell and the antibody is degraded. After determining
the best antibody and linker to suit the application, the site of conjugation onto the antibody
is another important consideration as the conjugation site greatly impacts the activity of
the drug conjugate. Most researchers use alkylation of reduced interchain disulfides,
acylation of lysine residues, or alkylation of genetically engineered cysteine residues to
combine the drug and linker to the antibody [47]. Figure 14 provides an overview of the key
design components of antibody-drug conjugates. Antibody-drug conjugations gives
researchers the ability to target key cells to elicit an antitumor response and warrant further
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research to determine effective designs that can deliver immunomodulatory agents to
tumors and associated immune cells/organs.

Figure 14: Key design components of antibody-drug conjugates. PK, pharmacokinetics. Figure adapted from
Ref [43].
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Conclusion
The development of immunomodulatory treatments has made tremendous strides
since the FDA approval of IFN-α to treat leukemia. Cancer immunotherapy has become a
vital asset for oncologists to treat cancer that has proven resistant to typical cancer therapies
including radiotherapy and chemotherapy. Immunotherapy offers a less toxic alternative
that has long-term curative effects to inhibit cancer growth, metastasis, and recurrence.
Though widely successful, many immunomodulatory agents in use are not effective in
patients with tumors that lack immunogenicity and can have adverse side effects when used
at high doses for long treatment windows. To solve these issues, researchers have
developed a wide range of biomaterials that can be used to deliver drugs systemically and
locally. By using these immunomodulatory biomaterials, researchers can target specific
immune cells and cancer cells, improve the pharmacokinetics and biodistribution of
immunotherapies, and improve the therapeutic window of approved and experimental
immunotherapies. As a result of the targeted delivery systems, biomaterials effectively use
low doses of immunomodulatory drugs such as IL-2, PD-1, or PD-L1 to elicit an effective
anticancer immune response without toxic side effects. Biomaterials also offer a modifiable
platform for spatiotemporal drug release to promote controlled, long-term, and responsive
treatments. Each biomaterial discussed in this review has key features that suit the intended
application of cancer immunity treatment. When considering an effective biomaterial for
immunomodulation, researchers must investigate which design parameters best suit their
intended use. Accordingly, we have reviewed hydrogels, scaffolds, microparticles,
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nanoparticles, and drug conjugates. The key design criteria of each biomaterial were
discussed, with a main focus on the effect of physical characteristics of the biomaterial on
drug delivery and its application. Immunomodulatory biomaterials such as those discussed
within this article have the potential to revolutionize cancer immunotherapy and improve
patient outcomes.
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